🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Ribonucleotide Reductase as a Driver of Breast Cancer Aggressiveness
Organization CLEVELAND CLINIC LERNER COM-CWRULocation CLEVELAND, UNITED STATESPosted 1 May 2024Deadline 30 Apr 2026 ⚠️
NIHUS FederalResearch GrantFY20253-D structure3-dimensional structure3D structureAddressAffinityApoptosisApoptosis PathwayBindingBlood leukocyteBreast CancerBreast Cancer CellBreast Cancer ModelBreast Cancer TreatmentBreast Cancer cell lineBreast NeoplasmsBreast TumorsBreast tumor cell lineBreast tumor modelCancer CauseCancer Cell GrowthCancer EtiologyCancersCardiac ToxicityCardiotoxicCardiotoxicityCatalysisCatalytic CoreCatalytic DomainCatalytic RegionCatalytic SiteCatalytic SubunitCell DeathCell LineCell Membrane PermeabilityCellLineChromosomal InstabilityChromosome InstabilityCryo-electron MicroscopyCryoelectron MicroscopyDNADNA DamageDNA InjuryDNA ReplicationDNA SynthesisDNA biosynthesisDNA polymerase beta 2DNA polymerase beta2DNA polymerase lambdaDataDeoxyribonucleic AcidDevelopmentDifluorodeoxycytidineDiseaseDisorderDockingDose LimitingDrug DesignDrug KineticsDrug usageDrugsElectron CryomicroscopyEnzyme GeneEnzymesEvaluationFDA approvedFoundationsFree RadicalsFutureGeneralized GrowthGenome InstabilityGenome StabilityGenomic InstabilityGenomic StabilityGenomicsGrowthHepatotoxic effectHepatotoxicityHeterograftHeterologous TransplantationHoloenzymesHumanHuman Cell LineHydrazonesLarge Subunit Ribonucleotide ReductaseLeadLeukocytesLeukocytes Reticuloendothelial SystemLiver ToxicityM PhaseM1 Subunit Ribonucleotide ReductaseMalignant Breast NeoplasmMalignant NeoplasmsMalignant TumorMammary CancerMammary NeoplasmsMarrow leukocyteMedicationMetabolicMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMetastatic breast cancerMiceMice MammalsMitosisMitosis StageModern ManMolecularMolecular Dynamics SimulationMolecular InteractionMouse Cell LineMurineMusMyelosuppressionNeoplasm MetastasisNucleotidesPBMCPatient CarePatient Care DeliveryPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPb elementPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacokineticsPol beta2Pol lambda DNA polymerasePopulationProductionProgrammed Cell DeathR1 GeneR1 Subunit Gene Ribonucleotide ReductaseR1 proteinR2 GeneRR2 GeneRRM1RRM1 geneRRM2RRM2 geneRecurrenceRecurrentRepressionResistanceResistance developmentResistant developmentRibonucleoside-Diphosphate Reductase M2 Chain GeneRibonucleotide ReductaseRibonucleotide Reductase InhibitorRibonucleotide Reductase M2 Polypeptide GeneRibonucleotide Reductase R1 SubunitRibonucleotide Reductase Small Chain GeneRibonucleotide Reductase SubunitRodent ModelSafetySecondary NeoplasmSecondary TumorSideSpecificityStrains Cell LinesStructureSurface Plasmon ResonanceSurvival RateTechniquesTissue GrowthToxic effectToxic effect on liver cellsToxicitiesTreatment FailureUpregulationWeightWhite Blood CellsWhite CellWomen's mortalityXenograftXenograft ModelXenograft procedureXenotransplantationadvanced breast canceradvanced diseaseadvanced illnessadvanced stage breast canceraggressive breast canceranalogbreast tumor cellcancer metastasiscare for patientscare of patientscaring for patientscombatcomputer based predictioncryo-EMcryoEMcryogenic electron microscopycultured cell linedFdCdFdCyddeath among femalesdeath among womendeath in femalesdeath in womendeath rate among womendeath rate in womendesigndesigningdetermine efficacydeveloping resistancedevelopmentaldrug efficacydrug usedrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefflux pumpenzyme activityevaluate efficacyexamine efficacyfemale deathfemale mortalitygemcitabineheavy metal Pbheavy metal leadhepatic toxicityhepatoxicityhuman modelimprovedin silicoinhibitormalignancymalignant breast tumormammary cancer modelmammary tumormammary tumor modelmembrane permeabilitymetastatic breast tumormetastatic mammary cancermetastatic mammary tumormodel of humanmolecular dynamicsmortality among femalesmortality among womenmortality in femalesmortality in womenmouse modelmurine modelnecrocytosisneoplasm/cancernovelnucleoside analogontogenypatient oriented outcomespre-clinicalpreclinicalpredictive modelingreplication stressresistantscreeningscreeningssenescencesenescentside effecttherapeutic targettherapy failurethree dimensional structuretumortumor cell metastasistumor growthuptakeweightswhite blood cellwhite blood corpusclewomen's deathwomen's death ratexeno-transplantxeno-transplantationxenograft transplant modelxenotransplant model
Applications closed.
Description preview
PROJECT SUMMARY
Despite the vast improvement in screening techniques and therapies, breast cancer remains the second leading
cause of cancer deaths in females worldwide. Approximately 30% of tumors progress to metastatic disease that
is incurable. Metastatic breast cancers are highly proliferative and thus rely on rapid deoxynucleotide production.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click